Plasma AR alterations and timing of intensified hormone treatment for prostate cancer: the STAMPEDE phase 3 randomized clinical trial
Leone, G. Orlando, F. Dutey-Magni, P. Vainauskas, O. Grist, E. Ciani, Y. Lall, S. Thakali, S. Wingate, A. Wetterskog, D.
Leone, G.
Orlando, F.
Dutey-Magni, P.
Vainauskas, O.
Grist, E.
Ciani, Y.
Lall, S.
Thakali, S.
Wingate, A.
Wetterskog, D.
Abstract
Description
Date
2025
Publisher
Collections
Keywords
Type
Article
Citation
Leone G, Orlando F, Dutey-Magni P, Vainauskas O, Grist E, Ciani Y, et al. Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer: the STAMPEDE Phase 3 Randomized Clinical Trial. JAMA Oncol. 2025 Feb 27;11(4):426-9. PubMed PMID: 40014335. Pubmed Central PMCID: PMC11869088 of androgen deprivation therapy alters selection of androgen receptor (AR) gene alterations within the gene body and/or enhancer region. on a patent with claims covering the PCF-SELECT methodology (WO2022/25897). Mr Vainauskas reported a patent pending for P032355US. Dr Sachdeva reported grants from Cancer Research UK, Prostate Cancer UK, the Prostate Cancer Foundation, the National Institute for Health and Care Research, The Urology Foundation, and the John Black Charitable Foundation; personal fees from Veracyte and Ipsen; and travel support from AIRA Matrix outside the submitted work. Prof Sydes reported nonfinancial support from Astellas, Clovis Oncology, Janssen, Novartis, Pfizer, and Sanofi-Aventis during the conduct of the study, as well as speaker fees and travel support from Eli Lilly and Janssen outside the submitted work. Dr McPhail reported personal fees from GlaxoSmithKline, Eisai, and Ipsen, as well as travel support from Ipsen and Bayer outside the submitted work. Dr O’Sullivan reported personal fees from AAA, Bayer, Astellas, Novartis, Johnson & Johnson, and Sanofi outside the submitted work. Prof James reported personal fees from Astellas and Janssen, as well as institutional grants from Astellas and Janssen during the conduct of the study. Dr Demichelis reported grants from the AIRC Foundation for Cancer Research in Italy during the conduct of the study, as well as being listed as co-inventor on a patent with claims covering the PCF-SELECT methodology (WO2022/25897). Prof Attard reported grants from Cancer Research UK, the AIRC Foundation for Cancer Research in Italy, Prostate Cancer UK, the Prostate Cancer Foundation, Janssen, Astellas, the John Black Charitable Foundation, Prostate Cancer Research, and the Medical Research Council during the conduct of the study; personal fees from Janssen, Astellas, Blue Earth Therapeutics, Bayer, Novartis, AstraZeneca, and Sanofi, and grants from Novartis and Agilent outside the submitted work; and a patent for claims covering the PCF-SELECT methodology issued (WO2022/25897) and a patent for abiraterone acetate with royalties paid. No other disclosures were reported. Epub 2025/02/27. eng.